An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54)
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54)
Aims: to compare the net cost of a tight blood pressure control policy with an angiotensin converting enzyme inhibitor (captopril) or β blocker (atenolol) in patients with Type 2 diabetes.
Design: a cost-effectiveness analysis based on outcomes and resources used in a randomized controlled trial and assumptions regarding the use of these therapies in a general practice setting. Setting: Twenty United Kingdom Prospective Diabetes Study Hospital-based clinics in England, Scotland and Northern Ireland.
Subjects: hypertensive patients (n = 758) with Type 2 diabetes (mean age 56 years, mean blood pressure 159/94 mmHg), 400 of whom were allocated to the angiotensin converting enzyme inhibitor captopril and 358 to the β blocker atenolol. Main outcome measures: Life expectancy and mean cost per patient.
Results: there was no statistically significant difference in life expectancy between groups. The cost per patient over the trial period was £6485 in the captopril group, compared with £5550 in the atenolol group, an average cost difference of £935 (95% confidence interval £188, £1682). This 14% reduction arose partly because of lower drug prices, and also because of significantly fewer and shorter hospitalizations in the atenolol group, and despite higher antidiabetic drug costs in the atenolol group.
Conclusions: treatment of hypertensive patients with Type 2 diabetes using atenolol or captopril was equally effective. However, total costs were significantly lower in the atenolol group.
Atenolol, Captopril, Cost, Economic evaluation, Hypertension, Type 2 diabetes
438-444
Gray, A.
3d36006e-b93b-459b-bf20-b413b4528a84
Clarke, P.
baf817ff-1927-4293-9e63-f7ac4488f623
Raikou, M.
9a7d69c6-5cba-4f47-8f54-06d7975aec0a
Adler, A.
d02dfdd6-ca6f-4cdc-91ab-8eb79ff94d7f
Stevens, R.
f6dd8ac2-050b-4103-9916-0baf993b59d7
Neil, A.
bcd21d55-bdc8-4b7e-8815-4ee344832213
Cull, C.
ae95233f-ce25-4c32-a5b9-368419e07826
Stratton, I.
772f25b9-23c0-4240-a3f6-1e76b03b172f
Holman, R.
336fb2f7-edb5-4d65-a7b0-465111cbd047
20 December 2001
Gray, A.
3d36006e-b93b-459b-bf20-b413b4528a84
Clarke, P.
baf817ff-1927-4293-9e63-f7ac4488f623
Raikou, M.
9a7d69c6-5cba-4f47-8f54-06d7975aec0a
Adler, A.
d02dfdd6-ca6f-4cdc-91ab-8eb79ff94d7f
Stevens, R.
f6dd8ac2-050b-4103-9916-0baf993b59d7
Neil, A.
bcd21d55-bdc8-4b7e-8815-4ee344832213
Cull, C.
ae95233f-ce25-4c32-a5b9-368419e07826
Stratton, I.
772f25b9-23c0-4240-a3f6-1e76b03b172f
Holman, R.
336fb2f7-edb5-4d65-a7b0-465111cbd047
Gray, A., Clarke, P., Raikou, M., Adler, A., Stevens, R., Neil, A., Cull, C., Stratton, I. and Holman, R.
,
the UKPDS Group
(2001)
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Diabetic Medicine, 18 (6), .
(doi:10.1046/j.1464-5491.2001.00485.x).
Abstract
Aims: to compare the net cost of a tight blood pressure control policy with an angiotensin converting enzyme inhibitor (captopril) or β blocker (atenolol) in patients with Type 2 diabetes.
Design: a cost-effectiveness analysis based on outcomes and resources used in a randomized controlled trial and assumptions regarding the use of these therapies in a general practice setting. Setting: Twenty United Kingdom Prospective Diabetes Study Hospital-based clinics in England, Scotland and Northern Ireland.
Subjects: hypertensive patients (n = 758) with Type 2 diabetes (mean age 56 years, mean blood pressure 159/94 mmHg), 400 of whom were allocated to the angiotensin converting enzyme inhibitor captopril and 358 to the β blocker atenolol. Main outcome measures: Life expectancy and mean cost per patient.
Results: there was no statistically significant difference in life expectancy between groups. The cost per patient over the trial period was £6485 in the captopril group, compared with £5550 in the atenolol group, an average cost difference of £935 (95% confidence interval £188, £1682). This 14% reduction arose partly because of lower drug prices, and also because of significantly fewer and shorter hospitalizations in the atenolol group, and despite higher antidiabetic drug costs in the atenolol group.
Conclusions: treatment of hypertensive patients with Type 2 diabetes using atenolol or captopril was equally effective. However, total costs were significantly lower in the atenolol group.
This record has no associated files available for download.
More information
Accepted/In Press date: 22 December 2000
Published date: 20 December 2001
Keywords:
Atenolol, Captopril, Cost, Economic evaluation, Hypertension, Type 2 diabetes
Identifiers
Local EPrints ID: 487086
URI: http://eprints.soton.ac.uk/id/eprint/487086
ISSN: 0742-3071
PURE UUID: d5ebac06-0391-4fc9-aca4-04b4cc0bcd73
Catalogue record
Date deposited: 13 Feb 2024 17:31
Last modified: 18 Mar 2024 04:01
Export record
Altmetrics
Contributors
Author:
A. Gray
Author:
P. Clarke
Author:
M. Raikou
Author:
A. Adler
Author:
R. Stevens
Author:
A. Neil
Author:
C. Cull
Author:
I. Stratton
Author:
R. Holman
Corporate Author: the UKPDS Group
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics